the dll3-targeting bite, tarlatamab, for the treatment of sclc
Published 2 years ago • 1K plays • Length 2:24Download video MP4
Download video MP3
Similar videos
-
3:40
the role of dll3-directed agents in treating sclc
-
3:22
evaluating tarlatamab in recurrent small cell lung cancer treatment
-
1:01
bi 764532: a novel t-cell engager for patients with dll3 sclc and nec
-
1:52
phase i trial of bi 764532, a t-cell engager for dll3-positive nec and sclc
-
5:38
amg 757: dll3 targeting, half-life extended bispecific t-cell engager immuno-oncology therapy, i...
-
0:38
advancing targeted therapies for sclc
-
18:16
dellphi-301 - fda approval of tarlatamab in patients w/ prev treated small cell lung cancer (sclc)
-
1:28
clinical trial: tarlatamab for small cell lung cancer (nct04885998)
-
2:53
the current treatment landscape for sclc
-
4:26
tarlatamab: mechanism of action and clinical success in small cell lung cancer │ pharmacology
-
1:15
dll3, a new biomarker for neuroendocrine tumors of the lung
-
0:37
amgen’s tarlatamab gets fda priority review for small cell lung cancer
-
3:24
novel immunotherapy agents on the horizon for lung cancer
-
1:14
recent developments in sclc
-
5:19
dll3-targeted and chemo-sensitive therapy
-
1:02
evaluating the role of systemic therapies in sclc
-
2:47
update from a phase 1 study of amg 757 in sclc
-
1:41
iasc wclc 2021: cx-2029 and amg 757 for lung cancer
-
3:00
personalizing small-cell lung cancer treatment: subsets, chemoimmunotherapy, and future prospects